Dermatologicals
Refine Search
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Beijing’s InnoCare Pharma has announced encouraging Phase II results for its novel TYK2 inhibitor, ICP-488, aimed at treating moderate-to-severe plaque psoriasis. 10 October 2024
Pharmaceutical
Spanish drugmaker Almirall closed Monday’s trading 8% higher after announcing its financial results for 2021. 21 February 2022
Biotechnology
A Phase III trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous urticaria (CSU), who were refractory to omalizumab, will stop due to futility based on a pre-specified interim analysis, marking a rare, albeit minor, set-back for the blockbuster monoclonal antibody (MAb). 21 February 2022
Pharmaceutical
Danish dermatology specialist LEO Pharma has appointed Brian Hilberdink new executive vice president and president of LEO Pharma Inc in the USA, effective March 14, 2022. 21 February 2022
Biotechnology
The US regulator has accepted for Priority Review a bid to broaden the label for the antibody Dupixent (dupilumab) in moderate-to-severe atopic dermatitis. 10 February 2022
Biotechnology
US biotech Regeneron Pharmaceuticals has announced financial results for the fourth quarter and full year 2021, that beat analysts’ estimates, boosted by demand for blockbuster drugs Dupixent (dupilumab) and Eylea (aflibercept), combined with higher sales of its COVID-19 therapy. 7 February 2022
Pharmaceutical
In the past year, French drugmaker Sanofi has seen its share price shoot up by 15%, outstripping many of its big pharma rivals. 4 February 2022
Biotechnology
According to a filing with the Securities and Exchange Commission, US healthcare giant Johnson & Johnson has determined that it will record an intangible asset impairment charge related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of atopic dermatitis (AD) and Hidradenitis suppurativa (HS). 4 February 2022
Biotechnology
Spanish dermatology specialist Almirall announced two collaborations in one on Monday. 31 January 2022
Biotechnology
Aurealis Therapeutics, a Swiss-Finnish synthetic biology and China-based Xbiome, an AI-based microbiome drug development company, on Friday announced that they have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational diabetic foot ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. 29 January 2022
Biotechnology
America traded shares of Immunocore Holdings were up 3.2% at $22.62 mid-morning, having hit $24.06 in earlier activity, after the UK biotech announced approval from the US Food and Drug Administration of Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). 26 January 2022
Biotechnology
Belgium biopharma UCB today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments. 24 January 2022
Biotechnology
More positive Phase III data add to the case for using Dupixent (dupilumab) to treat uncontrolled prurigo nodularis in adults. 20 January 2022
Pharmaceutical
Spanish dermatology focussed drugmaker Almirall and IRB Barcelona (the Institute for Biomedicine) today announced a research collaboration to identify new oral treatments for immune-inflammatory skin diseases with remaining high unmet medical needs using molecular glue degraders, a novel therapeutic modality. 18 January 2022
Pharmaceutical
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has released positive data from a patient satisfaction questionnaire related to tapinarof. 17 January 2022
Biotechnology
Having cast a shadow over the safety of the JAK inhibitor class of drugs in September last year, and delayed clearance of new drugs, on Friday the US Food and Drug Administration approved not one, but two new medicines in the category. 15 January 2022
Biotechnology
Chicagoan biotech AbbVie says its JAK inhibitor Rinvoq (upadacitinib) will likely generate half a billion dollars less in annual revenues by 2025, thanks to new labeling requirements in the USA. 13 January 2022
Biotechnology
Although topical Janus kinase (JAK) inhibitors were expected to become a major force in the atopic dermatitis (AD) space, the class of drugs suffered a major setback last year, when a US Food and Drug Administration review of a large clinical trial led the agency to conclude that JAK inhibitors lead to an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death. 11 January 2022
Biotechnology
Privately-held Danish dermatology specialist LEO Pharma yesterday revealed that the US Food and Drug Administration has approved Adbry (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable 29 December 2021
Biotechnology
German pharmaceutical firm Boehringer Ingelheim has published new data from the pivotal Phase II Effisayil trial in the New England Journal of Medicine. 23 December 2021
Pharmaceutical
Topical dermatology specialist DermBiont has raised $28 million in a series A financing, at the same time as acquiring clinical-stage biotech Chromaderm. 21 December 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze